Because of the notorious toxicity and lack of survival benefit of γ-secretase inhibitors in clinical application [18, 19], we evaluated evodiamine, a specific Notch-3 inhibitor that was reported to reverse tumor growth in non-small cell lung cancer with minimal side effects [12]. This evidence concerns the gene NOTCH3 and non-small cell lung carcinoma.